Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 5, 2002. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares and does not contain financial performance data for a specific fiscal period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding equity holdings and does not include financial statements.
Material Changes
The filing details specific changes in share ownership for directors and employee benefit trusts:
- SmithKline Beecham Employee Benefit Trust: On November 4, 2002, 45,578 Ordinary shares were transferred from the Trust to participants of the 1991 Share Option Plan.
- Dr. J.P. Garnier: Increased his personal interest by 32 Ordinary Share ADRs on October 30, 2002, at a price of $37.68 per share.
- GlaxoSmithKline US Retirement Savings Plan: The fund's holdings increased from 18,074,815 to 18,813,090 Ordinary Share ADRs on October 30, 2002, at an average price of $37.68.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document focuses solely on the mechanics of share transfers and director notifications.
Key Facts for Investor Verification
- Verify the total number of shares held by directors Dr. J.P. Garnier and Mr. J.D. Coombe, noting their indirect interest in the SmithKline Beecham Employee Benefit Trust and the US Retirement Savings Plan.
- Confirm the share price of $37.68 per ADR used for transactions on October 30, 2002.
- Review the total volume of shares transferred to the 1991 Share Option Plan participants (45,578 shares) to assess dilution or plan activity.